Compare SYM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYM | PRAX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 8.6B |
| IPO Year | 2021 | 2020 |
| Metric | SYM | PRAX |
|---|---|---|
| Price | $55.15 | $327.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $54.23 | ★ $519.60 |
| AVG Volume (30 Days) | ★ 2.2M | 425.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,246,922,000.00 | N/A |
| Revenue This Year | $24.66 | N/A |
| Revenue Next Year | $27.88 | $38,343.63 |
| P/E Ratio | $2,707.00 | ★ N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $16.32 | $26.70 |
| 52 Week High | $87.88 | $335.75 |
| Indicator | SYM | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 57.98 |
| Support Level | $53.06 | $314.35 |
| Resistance Level | $64.41 | $334.61 |
| Average True Range (ATR) | 4.18 | 17.67 |
| MACD | -0.10 | -0.67 |
| Stochastic Oscillator | 31.46 | 76.50 |
Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.